Reduced Vaccine Response to HZ/su in SLE
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorSeoul National University Hospital
About this trial
The goal of this observational study is to compare the vaccine response to the 2 doses of the adjuvanted herpes zoster subunit vaccine(HZ/su, "Shingrix") in patients with SLE and the age-, sex-, ethnicity-matched controls without autoimmune disease.
Eligibility criteria
Qualifiers
Males or females ≥ 50 years of age at time of consent
≥ 4 of the 1997 ACR13 or the 2012 SLICC/ACR criteria for SLE (14, 15)
Clinically stable SLE
Stable dose of one or more of the following immunosuppressive treatment ≥ 4 weeks
Disqualifiers
Pregnant or lactating females
Acute infection with temperature >38C at the time of vaccination
Previous anaphylactic response to vaccine components or to egg
History of Guillain-Barre syndrome or demyelinating syndromes
Trial design
Treatments tested in this trial
- Not listed
Trial groups
80 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov